A Pre-Recorded Web Conference: On 12/12/20 at 12:12 pm your time, click here for a Women’s Wellness: A United Sickle Cell Disease Virtual Conference

Countdown to the Women’s Wellness: A United Sickle Cell Disease Virtual Conference!
  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

Share this post

CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."